Akebia Therapeutics, Inc. (NASDAQ: AKBA) and Vifor Pharma Group. today announced they have entered into an exclusive license agreement to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Hot Corp. News Management Comments Mergers and Acquisitions

Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & CompanyMay 16, 2017 11:19 AM Akebia Therapeutics (AKBA) Secures $50M Investment at $14/Sh from Vifor Pharma for Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Dialysis FacilitiesMay 16, 2017 5:53 AM Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA ApprovalMay 15, 2017 4:05 PM